From the bench to a product: academics and entrepreneurship by Adang, Michael
I will provide a case study of my experience in trying to translate basic research discoveries 
into a product via a startup company. as an academic, a university professor—managing a 
grants program and students—why start a company? One of the things that drove me was 
my expertise in the area of Bacillus thuringiensis (Bt) toxins and their applications for insect 
control. If you stay in a research area long enough, you acquire insights into limitations in 
current technology and, if you have an entrepreneurial bent, you look for opportunities 
to apply those insights and solve problems. also, as you do basic research, whether in a 
university or private-sector laboratory, you may ask the question, “Where is it going?” 
You are building blocks of knowledge, but then you begin to look for opportunities to 
commercialize these technologies. In the 980s while at agrigenetics, I was involved in 
the process of patent writing. This experience proved invaluable when, at the University 
of Georgia, I began to evaluate research in my laboratory for potential inventions. My 
university was supportive in paying the costs of patenting, but then another bottleneck in 
the process emerged. You may have an invention, but the technology is at such an early 
stage in development, a large company is not likely to license the technology. So you look 
for ways to bridge the gap between the initial lab results and a product.
Despite the difficulties that plagued agricultural biotechnology in the 990s, I looked 
for opportunities in the agbiotech sector. It seemed that with consolidation in the industry 
dominated by a few large companies, there might be a niche for creating a startup company 
focused on insect control. On the other hand, despite having experience working in a 
biotech company, I questioned whether I had the energy and desire to enter the business 
world. But then things came together, helping me cross that line to form a company with 
the help of colleagues, albeit without a vision of the amount of time it would take. 
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Seeking New Strategies In Insect Control
In 003, Dr. Clifton Baile (University of Georgia, UGa) and I founded a company called 
InsectiGen, seeking new strategies for insect control. The UGa has a commercial alliance 
program that functions together with the Georgia research alliance to help professors 
who desire to be entrepreneurs combine their efforts with people who know how to build 
businesses. Located on campus at UGa is a Center for applied Genetics technologies, 
which makes available high-tech instrumentation to startup companies. In addition, the 
Georgia BioBusiness Center, directed by Dr. Margaret Wagner Dahl, helped provide 
infrastructure for founding InsectiGen.
InsectiGen went through the traditional startup phases of identifying intellectual 
property and market opportunities and writing a business plan. The Georgia research 
alliance has a program that provided funding to allow us to hire a professional to write 
the business plan. We moved to proof of concept and to development over the last year 
or so, securing capital and building infrastructure to go from a virtual company to a real 
company.
InsectiGen
I am fortunate to have Cliff as a motivational leader who has experience as a university 
professor, as a director of r&D at Monsanto, and as founder of seven biotech startups, as 
well as being director of a fairly large agbiotech company, MetaMorphix. He has provided 
the knowledge-base to make InsectiGen a reality. 
robert Ligon had retired after 5 years in informational technology entrepreneurship 
when he took my class at the University of Georgia on biotechnology. He became more 
interested and involved in the work, and ultimately served as president of InsectiGen. 
During that time, he helped develop the first business plan.
Having worked in the Bt-toxin area for 5 years, I provide scientific leadership. My 
work developing Bt plants has led to a number of patents and their commercialization 
in a small company. My colleague of many years, Don Dean, and I shared an NIH grant 
to design new Bt toxins for mosquito control; Don had the knowledge base, as well as 
the desire, to help me in this business endeavor. Dr. Mohd amir abdullah, who is paid 
from an USDa Small Business Innovation Grant awarded to InsectiGen May , 006, 
has been working in my lab on InsectiGen projects for  years.
Having an Impact
We founded InsectiGen in 003. The question we had to ask, in terms of finding a 
niche, was “How in the world, with such tremendous success with Bt corn, with Bt cot-
ton—with major players involved—can a couple of people in a little company actually 
have an impact and do something useful?”
We think that we can.
We know that there are unmet needs both in controlling insects that are currently 
only partially knocked down by Bt cotton and in developing new targets for Bt crops, 
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for example corn rootworm. We think that our technology will augment what’s already 
available.
I know that we can help improve the efficacy of Bt biopesticides, which is a commod-
ity-based global market of about $50 million. The numbers are a little hard to come by, 
but in the United States it’s a $76 million to $00 million market that has been stagnant 
for the last 0 years, partly due to Bt crops, because of limited biopesticide persistence, 
limited insect-control spectrum and development of insect resistance, but mostly because 
Bt biopesticides are relatively expensive at $5 to $0/acre. Therefore, at InsectiGen we 
are looking for strategies to make Bt biopesticides less expensive and more effective.
BtBooster
We came up with a new technology that was discovered from basic research: we call it 
BtBooster. It’s a protein-based agent that enhances the effect of Bt toxins. Stacked with 
Bt genes in transgenic plants or combined with Bt biopesticides, it improves control of 
insect pests.
In my laboratory we have been focused on the general question of how Bt toxins kill 
insects and how insects adapt to become resistant to Bt. Ingested Bt crystals dissolve in 
the insect gut where they are processed by proteases, converting protoxin to activated 
toxin. The toxins bind receptors located in the insect mid-gut, analogous to a lock-and-
key mechanism. The actual events involved in toxin action are quite complex, involving 
contact with multiple receptors, formation of a pre-pore structure followed by membrane 
insertion and cell death. 
From our basic research, we discovered that a fragment of a receptor protein made 
in E. coli—BtBooster—enhanced toxicity when mixed with Bt protein. This presented 
the possibility of taking a Bt plant that only marginally kills some insects and genetically 
stacking it with BtBooster peptide to achieve more-effective control of those insects. 
Our goal is to combine BtBooster with Bt proteins in transgenic crop plants and with 
Bt biopesticides.
There are many barriers that prevent a startup company from selling genetically engi-
neered cotton and corn. Therefore, it was necessary that InsectiGen license the BtBooster 
technology to a large company. In this case, DuPont licensed the use of BtBooster in 
cotton and other crops. InsectiGen will develop Bt biopesticides using BtBooster.
Funding and Sustainability
Founding partners and friends contributed funds to launch InsectiGen. The company’s 
founding was based on a vision rather than a specific technology, or even BtBooster. With 
a business plan we raised money from friends and “angel investors.” The Georgia research 
alliance was instrumental by matching dollar-for-dollar funds that InsectiGen spent on 
research. InsectiGen received an investment from the Georgia Venture Partner / Georgia 
Biosciences seed capital fund, monies put forth by Georgia as well as by universities to 
stimulate development of startup biotech companies. Having a licensing agreement with 
Dupont-Pioneer greatly enhanced our ability to raise funds.
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recently, InsectiGen was awarded a Phase  Small Business Innovative research (SBIr) 
grant from the USDa1. The Phase  grant supports the testing of a BtBooster-Bt biopesti-
cide in greenhouse trials. Pending a successful outcome of greenhouse studies, InsectiGen 
can apply for a Phase  grant to support field trials. Phase 3, actual commercialization of 
a biopesticide, would then be funded by InsectiGen.
You start out as an individual—a university professor—with entrepreneurial spirit, 
and one of the first things that people ask is, “What is your vision for the company?” 
People would ask, “are you a lifestyle company?” “Will it be a small company that will 
stay within your economic control, for a period of years?” “Or are you going to go the 
route of raising capital, first through investors and then through venture capitalists?” In 
the latter case your vision as the professor-entrepreneur has to be balanced by that of the 
CEO, by your investors, by your directors on your board. You quickly learn that you have 
less control than you ever expected, which you have to be willing to accept.
another thing that I’ve learned is that, in spite of what you may think, professors 
are not the best managers. running an academic research group is quite different than 
managing science in a startup biotech company. In business, even at the scientific level, 
at some point you may need people who are better managers.
Ethics and time Challenges
You also must deal with ethical conflicts between the role of the entrepreneur—which 
can be time-consuming—and the role of the professor with obligations to students, to 
postdocs, to research colleagues, and to others in the university milieu. You must learn 
to balance teaching responsibilities and a university-based research program with time 
spent on company business. Issues of potential conflict between academic responsibilities 
and the biotech startup are addressed through a formal policy system based on open-
disclosure with university administration and researchers in the academic laboratory. In 
my case, the associate dean for research in the College of agriculture and Environmental 
Sciences is the hands-on manager for conflicts, with whom I have to dialogue in order 
to circumvent problems.
time management is one of the major challenges. In my lab we have grants from USDa 
and NIH, and as well as InsectiGen-sponsored research. Between science-management 
issues, research duties, teaching, and company obligations, the process of academics as 
entrepreneurs can be made to work, but it truly is a struggle.
1William Goldner’s description of the SBIr Program is on pp. 49–56.
You also must deal with ethical conflicts between the role of the 
entrepreneur—which can be time-consuming—and the role of 
the professor with obligations to students, etc.
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In Summary
I have tried to provide a snapshot of my personal experience and I will conclude by saying 
that it’s both challenging and rewarding. as a professor you’re never sure what the final 
outcome of these endeavors is going to be. One of the things I’m interested in doing is 
communicating with faculty at other universities to address common issues that come 
up in business-related endeavors.
and then, finally, a parting thought from alejandro Zaffaroni, who has started a number 
of companies including Hybritech: you learn that the business of commercializing products 
is very different from academia, particularly in terms of the number of challenges—and 
failures—that you have to deal with.
The business of commercializing products is very different from 
academia, particularly in terms of the number of challenges—
and failures—that you have to deal with.
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micHael adang received his BS in microbiology from 
Indiana University in 974 and his MSc and PhD in bac-
teriology from Washington State University in 978 and 
98. He is a professor of entomology, biochemistry and 
molecular biology at the University of Georgia with ninety 
journal articles and book chapters and thirteen US patents 
to his credit. 
as a senior research scientist at agrigenetics Corp. in Madison, Wisconsin, 
98–988, Dr. adang developed transgenic plants expressing proteins from 
Bacillus thuringiensis (Bt). among his inventions are methods for expressing Bt 
genes in plants and a codon-usage method to optimize Bt-gene expression in 
plants. These technologies have been used worldwide with significant impact on 
pest control in agriculture. 
Since 988, his research has focused on receptors that determine Bt toxicity 
to insects. His laboratory was the first to discover a Bt-toxin receptor, with basic 
and applied implications for Bt-plant development and usage.
adang has consulted for the government, Mycogen Corporation and Dow 
agrosciences. His global activities in the intellectual-property area include patent 
preparation and prosecution activities with approximately ten law firms over a 
0-year period. In 003, he co-founded InsectiGen, a start-up company focused 
on discovery and engineering of proteins for insect control.
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